Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Циркулирующие опухолевые клетки: биология, методы выделения, клиническое значение при раке молочной железы
Циркулирующие опухолевые клетки: биология, методы выделения, клиническое значение при раке молочной железы
Ненахова Ю.Н., Лядов В.К., Поддубная И.В. Циркулирующие опухолевые клетки: биология, методы выделения, клиническое значение при раке молочной железы. Современная Онкология. 2016; 18 (3): 76–82.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Рак молочной железы является наиболее распространенной женской онкопатологией в мире. Основная причина смертности больных – метастазирование. Современное состояние медицины позволяет излечивать первичную опухоль, но зачастую является недостаточно эффективным для контроля за развитием метастатической болезни. Важное значение в реализации метастатического каскада играют циркуляция и выживание в кровотоке опухолевых клеток. В этой статье мы постарались обобщить и представить данные литературы по изучению циркулирующих опухолевых клеток у больных раком молочной железы.
Ключевые слова: рак молочной железы, циркулирующие опухолевые клетки, эпителиально-мезенхимальный переход, метастазирование, предикторная значимость, прогноз заболевания, методы идентификации и исследования.
Key words: breast cancer, circulating tumor cells, epithelial-mesenchymal transition, metastasis, predictive significance, prognosis, methods of identification and research.
Ключевые слова: рак молочной железы, циркулирующие опухолевые клетки, эпителиально-мезенхимальный переход, метастазирование, предикторная значимость, прогноз заболевания, методы идентификации и исследования.
________________________________________________
Key words: breast cancer, circulating tumor cells, epithelial-mesenchymal transition, metastasis, predictive significance, prognosis, methods of identification and research.
Полный текст
Список литературы
1. Давыдов М.И., Аксeль Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. 2014. / Davydov M.I., Aksel' E.M. Statistika zlokachestvennykh novoobrazovanii v Rossii i stranakh SNG v 2012 g. 2014. [in Russian]
2. Mirza AN, Mirza NQ, Vlastos G et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10–26.
3. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl Med 2002; 347: 1233–41.
4. Fehm T, Solomayer EF, Meng S еt al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7 (2): 171–85.
5. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 1869; 14: 146–9.
6. Ковалев А.А., Грудинская Т.А., Кузнецова Т.П. и др. Гетерогенность циркулирующих опухолевых клеток. Онкология. 2012; 14 (2): 126–9. / Kovalev A.A., Grudinskaia T.A., Kuznetsova T.P. i dr. Geterоgennost' tsirkuliruiushchikh opukholevykh kletok. Onkologiia. 2012; 14 (2): 126–9. [in Russian]
7. Пучинская М.В. Эпителиально-мезенхимальный переход в норме и патологии. Арх. патологии. 2015; 1: 75–83. / Puchinskaia M.V. Epitelial'no-mezenkhimal'nyi perekhod v norme i patologii. Arkh. patologii. 2015; 1: 75–83. [in Russian]
8. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995; 154: 8–20.
9. Ковалев А.А. Циркулирующие опухолевые клетки. Здоровье Украины. 2012; июнь: 36–7. / Kovalev A.A. Tsirkuliruiushchie opukholevye kletki. Zdorov'e Ukrainy. 2012; iiun': 36–7. [in Russian]
10. Fidler I, Kripke M. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893–5.
11. Fehm T, Solomayer E, Meng S. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7 (2): 171–85.
12. Vona G, Sabile A, Louha M et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000; 156 (1): 57–63.
13. Зубцов Д.А., Зубцова Ж.И., Лавров А.В. и др. Циркулирующие опухолевые клетки при раке молочной железы (ЦОК): прогностическая значимость и методы выделения. Труды МФТИ. 2012; 4 (3): 18–26. / Zubtsov D.A., Zubtsova Zh.I., Lavrov A.V. i dr. Tsirkuliruiushchie opukholevye kletki pri rake molochnoi zhelezy (TsOK): prognosticheskaia znachimost' i metody vydeleniia. Trudy MFTI. 2012; 4 (3): 18–26. [in Russian]
14. Alix-Panabieres C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 2012; 195: 69–76.
15. Лядов В.К., Скрыпникова М.А., Попова О.П. Выделение циркулирующих в крови опухолевых клеток методом «изоляции по размеру (ISET)» (обзор). Вопр. онкологии. 2014; 60 (5): 548–52. / Liadov V.K., Skrypnikova M.A., Popova O.P. Vydelenie tsirkuliruiushchikh v krovi opukholevykh kletok metodom «izoliatsii po razmeru (ISET)» (obzor). Vopr. onkologii. 2014; 60 (5): 548–52. [in Russian]
16. Исмаилова Г., Laget S, Paterlini-Bréchot P. Диагностика циркулирующих опухолевых клеток с помощью технологии ISET и их молекулярная характеристика для жидкостной биопсии. Клин. медицина Казахстана. 2015; 1 (35): 15–20. / Ismailova G., Laget S, Paterlini-Bréchot P. Diagnostika tsirkuliruiushchikh opukholevykh kletok s pomoshch'iu tekhnologii ISET i ikh molekuliarnaia kharakteristika dlia zhidkostnoi biopsii. Klin. meditsina Kazakhstana. 2015; 1 (35): 15–20. [in Russian]
17. Бжадуг О.Б., Тупицын Н.Н., Тюляндин С.А. Значение выявления микрометастазов в крови и костном мозге у больных раком молочной железы. Современная Онкология. 2004; 6 (4): 149–54. / Bzhadug O.B., Tupitsyn N.N., Tiuliandin S.A. Znachenie vyiavleniia mikrometastazov v krovi i kostnom mozge u bol'nykh rakom molochnoi zhelezy. Journal of Modern Oncology. 2004; 6 (4): 149–54. [in Russian]
18. Xenidis N, Markos V, Apostolaki S et al. Clinical relevance of circulating CK_19 mRNA_positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 2007; 10: 1623–31.
19. Smith BM, Slade MJ, English J et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantative polimerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000; 7: 1432–9.
20. Cristofanilli M, Budd G, Ellis M et al. Circulating tumor cells, disease progression, and survival in metastatic breast. Cancer Semin Oncol 2006; 33: 9–14.
21. Gafforio JJ, Serrano MJ, Sanches-Rovira P et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 2003; 107 (6): 984–90.
22. Бжадуг О.Б., Гривцова Л.Ю., Тупицын Н.Н. и др. Циркулирующие опухолевые клетки в крови больных местно-распространенным и диссеминированным раком молочной железы. Вестн. РОНЦ им. Н.Н.Блохина РАМН. 2007; 3: 19–22. / Bzhadug O.B., Grivtsova L.Iu., Tupitsyn N.N. i dr. Tsirkuliruiushchie opukholevye kletki v krovi bol'nykh mestno-rasprostranennym i disseminirovannym rakom molochnoi zhelezy. Vestn. RONTs im. N.N.Blokhina RAMN. 2007; 3: 19–22. [in Russian]
23. Apostolaki S, Perraki M, Pallis A et al. Circulating HER2 mRNA_positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 2007; 18 (5): 851–8.
24. Bidard FC, Matiot C, Delaloge S et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 4 (2): 729–33.
25. Bidard FС, Proudhona С, Pierga J. Circulating tumor cells in breast cancer. Mol Oncol 2016; 10: 418–30.
26. Riethdorf S, Muller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring of breast cancer patient treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16 (9): 79–93.
27. Camara O, Rengsberger M, Egbe A et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 2007; 9: 1484–92.
28. Alpers I, Brandt В. Minimal Residual Disease (MRD) in cancer of solid tumors. Haemopoesis Immunology 2007; 4: 14–37.
29. Meng S, Tripathy D, Shete S et al. HER2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004; 101 (25): 9393–8.
30. Pestrin M, Bessi S, Galardi F et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009; 118 (3): 523–30.
31. Alix-Panabires C, Muller V, Pantel K. Current status in human breast cancer micrometastasis. Curr Opin Oncol 2007; 6: 558–63.
2. Mirza AN, Mirza NQ, Vlastos G et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10–26.
3. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl Med 2002; 347: 1233–41.
4. Fehm T, Solomayer EF, Meng S еt al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7 (2): 171–85.
5. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 1869; 14: 146–9.
6. Kovalev A.A., Grudinskaia T.A., Kuznetsova T.P. i dr. Geterоgennost' tsirkuliruiushchikh opukholevykh kletok. Onkologiia. 2012; 14 (2): 126–9. [in Russian]
7. Puchinskaia M.V. Epitelial'no-mezenkhimal'nyi perekhod v norme i patologii. Arkh. patologii. 2015; 1: 75–83. [in Russian]
8. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995; 154: 8–20.
9. Kovalev A.A. Tsirkuliruiushchie opukholevye kletki. Zdorov'e Ukrainy. 2012; iiun': 36–7. [in Russian]
10. Fidler I, Kripke M. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893–5.
11. Fehm T, Solomayer E, Meng S. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7 (2): 171–85.
12. Vona G, Sabile A, Louha M et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000; 156 (1): 57–63.
13. Zubtsov D.A., Zubtsova Zh.I., Lavrov A.V. i dr. Tsirkuliruiushchie opukholevye kletki pri rake molochnoi zhelezy (TsOK): prognosticheskaia znachimost' i metody vydeleniia. Trudy MFTI. 2012; 4 (3): 18–26. [in Russian]
14. Alix-Panabieres C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 2012; 195: 69–76.
15. Liadov V.K., Skrypnikova M.A., Popova O.P. Vydelenie tsirkuliruiushchikh v krovi opukholevykh kletok metodom «izoliatsii po razmeru (ISET)» (obzor). Vopr. onkologii. 2014; 60 (5): 548–52. [in Russian]
16. Ismailova G., Laget S, Paterlini-Bréchot P. Diagnostika tsirkuliruiushchikh opukholevykh kletok s pomoshch'iu tekhnologii ISET i ikh molekuliarnaia kharakteristika dlia zhidkostnoi biopsii. Klin. meditsina Kazakhstana. 2015; 1 (35): 15–20. [in Russian]
17. Bzhadug O.B., Tupitsyn N.N., Tiuliandin S.A. Znachenie vyiavleniia mikrometastazov v krovi i kostnom mozge u bol'nykh rakom molochnoi zhelezy. Journal of Modern Oncology. 2004; 6 (4): 149–54. [in Russian]
18. Xenidis N, Markos V, Apostolaki S et al. Clinical relevance of circulating CK_19 mRNA_positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 2007; 10: 1623–31.
19. Smith BM, Slade MJ, English J et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantative polimerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000; 7: 1432–9.
20. Cristofanilli M, Budd G, Ellis M et al. Circulating tumor cells, disease progression, and survival in metastatic breast. Cancer Semin Oncol 2006; 33: 9–14.
21. Gafforio JJ, Serrano MJ, Sanches-Rovira P et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 2003; 107 (6): 984–90.
22. Bzhadug O.B., Grivtsova L.Iu., Tupitsyn N.N. i dr. Tsirkuliruiushchie opukholevye kletki v krovi bol'nykh mestno-rasprostranennym i disseminirovannym rakom molochnoi zhelezy. Vestn. RONTs im. N.N.Blokhina RAMN. 2007; 3: 19–22. [in Russian]
23. Apostolaki S, Perraki M, Pallis A et al. Circulating HER2 mRNA_positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 2007; 18 (5): 51–8.
24. Bidard FC, Matiot C, Delaloge S et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 4 (2): 729–33.
25. Bidard FС, Proudhona С, Pierga J. Circulating tumor cells in breast cancer. Mol Oncol 2016; 10: 418–30.
26. Riethdorf S, Muller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring of breast cancer patient treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16 (9): 79–93.
27. Camara O, Rengsberger M, Egbe A et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 2007; 9: 1484–92.
28. Alpers I, Brandt В. Minimal Residual Disease (MRD) in cancer of solid tumors. Haemopoesis Immunology 2007; 4: 14–37.
29. Meng S, Tripathy D, Shete S et al. HER2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004; 101 (25): 9393–8.
30. Pestrin M, Bessi S, Galardi F et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009; 118 (3): 523–30.
31. Alix-Panabires C, Muller V, Pantel K. Current status in human breast cancer micrometastasis. Curr Opin Oncol 2007; 6: 558–63.
2. Mirza AN, Mirza NQ, Vlastos G et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10–26.
3. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl Med 2002; 347: 1233–41.
4. Fehm T, Solomayer EF, Meng S еt al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7 (2): 171–85.
5. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 1869; 14: 146–9.
6. Ковалев А.А., Грудинская Т.А., Кузнецова Т.П. и др. Гетерогенность циркулирующих опухолевых клеток. Онкология. 2012; 14 (2): 126–9. / Kovalev A.A., Grudinskaia T.A., Kuznetsova T.P. i dr. Geterоgennost' tsirkuliruiushchikh opukholevykh kletok. Onkologiia. 2012; 14 (2): 126–9. [in Russian]
7. Пучинская М.В. Эпителиально-мезенхимальный переход в норме и патологии. Арх. патологии. 2015; 1: 75–83. / Puchinskaia M.V. Epitelial'no-mezenkhimal'nyi perekhod v norme i patologii. Arkh. patologii. 2015; 1: 75–83. [in Russian]
8. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995; 154: 8–20.
9. Ковалев А.А. Циркулирующие опухолевые клетки. Здоровье Украины. 2012; июнь: 36–7. / Kovalev A.A. Tsirkuliruiushchie opukholevye kletki. Zdorov'e Ukrainy. 2012; iiun': 36–7. [in Russian]
10. Fidler I, Kripke M. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893–5.
11. Fehm T, Solomayer E, Meng S. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7 (2): 171–85.
12. Vona G, Sabile A, Louha M et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000; 156 (1): 57–63.
13. Зубцов Д.А., Зубцова Ж.И., Лавров А.В. и др. Циркулирующие опухолевые клетки при раке молочной железы (ЦОК): прогностическая значимость и методы выделения. Труды МФТИ. 2012; 4 (3): 18–26. / Zubtsov D.A., Zubtsova Zh.I., Lavrov A.V. i dr. Tsirkuliruiushchie opukholevye kletki pri rake molochnoi zhelezy (TsOK): prognosticheskaia znachimost' i metody vydeleniia. Trudy MFTI. 2012; 4 (3): 18–26. [in Russian]
14. Alix-Panabieres C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 2012; 195: 69–76.
15. Лядов В.К., Скрыпникова М.А., Попова О.П. Выделение циркулирующих в крови опухолевых клеток методом «изоляции по размеру (ISET)» (обзор). Вопр. онкологии. 2014; 60 (5): 548–52. / Liadov V.K., Skrypnikova M.A., Popova O.P. Vydelenie tsirkuliruiushchikh v krovi opukholevykh kletok metodom «izoliatsii po razmeru (ISET)» (obzor). Vopr. onkologii. 2014; 60 (5): 548–52. [in Russian]
16. Исмаилова Г., Laget S, Paterlini-Bréchot P. Диагностика циркулирующих опухолевых клеток с помощью технологии ISET и их молекулярная характеристика для жидкостной биопсии. Клин. медицина Казахстана. 2015; 1 (35): 15–20. / Ismailova G., Laget S, Paterlini-Bréchot P. Diagnostika tsirkuliruiushchikh opukholevykh kletok s pomoshch'iu tekhnologii ISET i ikh molekuliarnaia kharakteristika dlia zhidkostnoi biopsii. Klin. meditsina Kazakhstana. 2015; 1 (35): 15–20. [in Russian]
17. Бжадуг О.Б., Тупицын Н.Н., Тюляндин С.А. Значение выявления микрометастазов в крови и костном мозге у больных раком молочной железы. Современная Онкология. 2004; 6 (4): 149–54. / Bzhadug O.B., Tupitsyn N.N., Tiuliandin S.A. Znachenie vyiavleniia mikrometastazov v krovi i kostnom mozge u bol'nykh rakom molochnoi zhelezy. Journal of Modern Oncology. 2004; 6 (4): 149–54. [in Russian]
18. Xenidis N, Markos V, Apostolaki S et al. Clinical relevance of circulating CK_19 mRNA_positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 2007; 10: 1623–31.
19. Smith BM, Slade MJ, English J et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantative polimerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000; 7: 1432–9.
20. Cristofanilli M, Budd G, Ellis M et al. Circulating tumor cells, disease progression, and survival in metastatic breast. Cancer Semin Oncol 2006; 33: 9–14.
21. Gafforio JJ, Serrano MJ, Sanches-Rovira P et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 2003; 107 (6): 984–90.
22. Бжадуг О.Б., Гривцова Л.Ю., Тупицын Н.Н. и др. Циркулирующие опухолевые клетки в крови больных местно-распространенным и диссеминированным раком молочной железы. Вестн. РОНЦ им. Н.Н.Блохина РАМН. 2007; 3: 19–22. / Bzhadug O.B., Grivtsova L.Iu., Tupitsyn N.N. i dr. Tsirkuliruiushchie opukholevye kletki v krovi bol'nykh mestno-rasprostranennym i disseminirovannym rakom molochnoi zhelezy. Vestn. RONTs im. N.N.Blokhina RAMN. 2007; 3: 19–22. [in Russian]
23. Apostolaki S, Perraki M, Pallis A et al. Circulating HER2 mRNA_positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 2007; 18 (5): 851–8.
24. Bidard FC, Matiot C, Delaloge S et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 4 (2): 729–33.
25. Bidard FС, Proudhona С, Pierga J. Circulating tumor cells in breast cancer. Mol Oncol 2016; 10: 418–30.
26. Riethdorf S, Muller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring of breast cancer patient treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16 (9): 79–93.
27. Camara O, Rengsberger M, Egbe A et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 2007; 9: 1484–92.
28. Alpers I, Brandt В. Minimal Residual Disease (MRD) in cancer of solid tumors. Haemopoesis Immunology 2007; 4: 14–37.
29. Meng S, Tripathy D, Shete S et al. HER2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004; 101 (25): 9393–8.
30. Pestrin M, Bessi S, Galardi F et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009; 118 (3): 523–30.
31. Alix-Panabires C, Muller V, Pantel K. Current status in human breast cancer micrometastasis. Curr Opin Oncol 2007; 6: 558–63.
________________________________________________
2. Mirza AN, Mirza NQ, Vlastos G et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10–26.
3. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl Med 2002; 347: 1233–41.
4. Fehm T, Solomayer EF, Meng S еt al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7 (2): 171–85.
5. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 1869; 14: 146–9.
6. Kovalev A.A., Grudinskaia T.A., Kuznetsova T.P. i dr. Geterоgennost' tsirkuliruiushchikh opukholevykh kletok. Onkologiia. 2012; 14 (2): 126–9. [in Russian]
7. Puchinskaia M.V. Epitelial'no-mezenkhimal'nyi perekhod v norme i patologii. Arkh. patologii. 2015; 1: 75–83. [in Russian]
8. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995; 154: 8–20.
9. Kovalev A.A. Tsirkuliruiushchie opukholevye kletki. Zdorov'e Ukrainy. 2012; iiun': 36–7. [in Russian]
10. Fidler I, Kripke M. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893–5.
11. Fehm T, Solomayer E, Meng S. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7 (2): 171–85.
12. Vona G, Sabile A, Louha M et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000; 156 (1): 57–63.
13. Zubtsov D.A., Zubtsova Zh.I., Lavrov A.V. i dr. Tsirkuliruiushchie opukholevye kletki pri rake molochnoi zhelezy (TsOK): prognosticheskaia znachimost' i metody vydeleniia. Trudy MFTI. 2012; 4 (3): 18–26. [in Russian]
14. Alix-Panabieres C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 2012; 195: 69–76.
15. Liadov V.K., Skrypnikova M.A., Popova O.P. Vydelenie tsirkuliruiushchikh v krovi opukholevykh kletok metodom «izoliatsii po razmeru (ISET)» (obzor). Vopr. onkologii. 2014; 60 (5): 548–52. [in Russian]
16. Ismailova G., Laget S, Paterlini-Bréchot P. Diagnostika tsirkuliruiushchikh opukholevykh kletok s pomoshch'iu tekhnologii ISET i ikh molekuliarnaia kharakteristika dlia zhidkostnoi biopsii. Klin. meditsina Kazakhstana. 2015; 1 (35): 15–20. [in Russian]
17. Bzhadug O.B., Tupitsyn N.N., Tiuliandin S.A. Znachenie vyiavleniia mikrometastazov v krovi i kostnom mozge u bol'nykh rakom molochnoi zhelezy. Journal of Modern Oncology. 2004; 6 (4): 149–54. [in Russian]
18. Xenidis N, Markos V, Apostolaki S et al. Clinical relevance of circulating CK_19 mRNA_positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 2007; 10: 1623–31.
19. Smith BM, Slade MJ, English J et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantative polimerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000; 7: 1432–9.
20. Cristofanilli M, Budd G, Ellis M et al. Circulating tumor cells, disease progression, and survival in metastatic breast. Cancer Semin Oncol 2006; 33: 9–14.
21. Gafforio JJ, Serrano MJ, Sanches-Rovira P et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 2003; 107 (6): 984–90.
22. Bzhadug O.B., Grivtsova L.Iu., Tupitsyn N.N. i dr. Tsirkuliruiushchie opukholevye kletki v krovi bol'nykh mestno-rasprostranennym i disseminirovannym rakom molochnoi zhelezy. Vestn. RONTs im. N.N.Blokhina RAMN. 2007; 3: 19–22. [in Russian]
23. Apostolaki S, Perraki M, Pallis A et al. Circulating HER2 mRNA_positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 2007; 18 (5): 51–8.
24. Bidard FC, Matiot C, Delaloge S et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 4 (2): 729–33.
25. Bidard FС, Proudhona С, Pierga J. Circulating tumor cells in breast cancer. Mol Oncol 2016; 10: 418–30.
26. Riethdorf S, Muller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring of breast cancer patient treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16 (9): 79–93.
27. Camara O, Rengsberger M, Egbe A et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 2007; 9: 1484–92.
28. Alpers I, Brandt В. Minimal Residual Disease (MRD) in cancer of solid tumors. Haemopoesis Immunology 2007; 4: 14–37.
29. Meng S, Tripathy D, Shete S et al. HER2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004; 101 (25): 9393–8.
30. Pestrin M, Bessi S, Galardi F et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009; 118 (3): 523–30.
31. Alix-Panabires C, Muller V, Pantel K. Current status in human breast cancer micrometastasis. Curr Opin Oncol 2007; 6: 558–63.
Авторы
Ю.Н.Ненахова*1, В.К.Лядов1,2, И.В.Поддубная1,3
1 ФГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1;
2 ФГАУ Лечебно-реабилитационный центр Минздрава России. 125367, Россия, Москва, Иваньковское ш., д. 3;
3 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*lyullikalya@mail.ru
1 Russian Medical Academy for Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1;
2 Medical and Rehabilitation Center of the Ministry of Health of the Russian Federation.
125367, Russian Federation, Moscow, Ivan’kovskoe sh., d. 3;
3 N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*lyullikalya@mail.ru
1 ФГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1;
2 ФГАУ Лечебно-реабилитационный центр Минздрава России. 125367, Россия, Москва, Иваньковское ш., д. 3;
3 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*lyullikalya@mail.ru
________________________________________________
1 Russian Medical Academy for Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1;
2 Medical and Rehabilitation Center of the Ministry of Health of the Russian Federation.
125367, Russian Federation, Moscow, Ivan’kovskoe sh., d. 3;
3 N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*lyullikalya@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.